ReviewTowards a better understanding of the clinical association of anti-DFS70 autoantibodies
Section snippets
Take-home messages
- •
potential clinical associations of anti-DFS70 antibodies remains speculative and future, well defined, studies are required to provide more insights.
- •
HEp-2 cells can be used to screen for anti-DFS70 antibodies, but their presence should be confirmed using a specific test for anti-DFS70 antibodies (i.e. ELISA, CIA or by immunoadsorption).
Competing interests
M. Mahler is employed at Inova Diagnostics selling autoantibody assays. The other authors received consultant fees from Inova Diagnostics in the past.
References (26)
- et al.
Autoantibodies in interstitial cystitis
J Urol
(1994) - et al.
Specific chemoluminescence and immunoasdorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence
Clin Chim Acta
(2015) - et al.
Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: preferential targeting of DFS70/LEDGFp75 over its interacting partner MeCP2
Clin Immunol
(2015) - et al.
Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells
Autoimmun Rev
(2009) - et al.
Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems
Autoimmun Rev
(2014) - et al.
Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome
Autoimmun Rev
(2005) - et al.
Does seronegative antiphospholipid syndrome really exist?
Autoimmun Rev
(2012) Clinical significance of antiphosphatidylethanolamine antibodies in the so-called “seronegative antiphospholipid syndrome”
Autoimmun Rev
(2009)- et al.
Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases
Autoimmun Rev
(2011) - et al.
The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases
Clin Dev Immunol 2012
(2012)
Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us?
Arthritis Rheum
Thrombophilia associated with anti-DFS70 autoantibodies
PLoS One
The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding
Clin Exp Med
Cited by (58)
Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence?
2024, Autoimmunity ReviewsThe antinuclear antibody dense fine speckled pattern and possible clinical associations: An indication of a proinflammatory microenvironment
2021, Journal of Immunological MethodsCitation Excerpt :Since its association with interstitial cystitis in 1994 (Ochs et al., 1994), there have been additional reports linking the ANA-DFS pattern with a variety of other non-SARD diseases, especially atopic dermatitis (Ochs et al., 2000), and even healthy individuals (Watanabe et al., 2004). Studies have shown associations with atopy (asthma), other skin disorders (psoriasis and alopecia areata), Vogt-Harada syndrome, Hashimoto's thyroiditis, ocular disease, prostate cancer, chronic fatigue syndrome, and fibromyalgia (Ochs et al., 2016; Ochs et al., 2000; Watanabe et al., 2004; Mahler et al., 2016; Takeichi et al., 2010; Okamoto et al., 2004; Sendscheid et al., 2019; Jeong et al., 2019). Recently there has been increased interest in the potential use of anti-DFS70/LEDGF as a marker to exclude the diagnosis of SARD, an idea supported by prior studies that demonstrated the rare prevalence of anti-DFS70/LEDGF in SARD patients compared to healthy individuals (Mariz et al., n.d.; Mahler et al., 2012a).
Clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies testing
2020, Journal of Immunological MethodsAntihistone and antispliceosome antibodies
2020, Systemic Lupus Erythematosus: Basic, Applied and Clinical AspectsDense fine speckled nuclear immunofluorescence: A mildly reassuring antinuclear antibody pattern meriting consideration
2023, Immunity, Inflammation and Disease